Chinese Peptide Company: difference between revisions
Diff·revision 38 → 39·02:28, 6 Feb 2025
Difference between revision 38 and revision 39 of Chinese Peptide Company. 3 lines changed; the page grew by 417 bytes.
| Revision 38 — 22:56, 30 Jan 2025 eGFR_Esme (talk) label community tally as self-reported 7,558 bytes ±0 | Revision 39 — 02:28, 6 Feb 2025 VerifyFirstVida (talk) consistent en dashes in ranges 7,975 bytes +417 | ||
|---|---|---|---|
| 52 | Reports submitted on CPC material to July 2026 span a wider set of analytes than for most organisations covered here, including several sequences outside the incretin range. Reported [[Area percent purity|area percent]] figures have been high, and in the subset where the certificate reported both purity and water, purchaser-computed [[Peptide content|peptide content]] figures have been consistent with the certificate's own arithmetic.{{r|reports,usp1503}} | 52 | Reports submitted on CPC material to July 2026 span a wider set of analytes than for most organisations covered here, including several sequences outside the incretin range. Reported [[Area percent purity|area percent]] figures have been high, and in the subset where the certificate reported both purity and water, purchaser-computed [[Peptide content|peptide content]] figures have been consistent with the certificate's own arithmetic.{{r|reports,usp1503}} |
| 53 | 53 | ||
| + | 54 | That is the strongest form of documentary agreement recorded on any of these articles, and it is still not a statement about the organisation's output: the samples were purchaser-selected and were not drawn blind.{{r|reports,iso17025}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 59 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 61 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 60 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 62 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 63 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 61 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 64 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 62 | 65 |